Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CYTK | CYTOKINETICS INC | 2025-10-16 18:56:45 | 58.7 | -0.26 | -0.44 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | 0001061983 | CYTOKINETICS INC | US23282W6057 | 549300BE5DY1HW7IHA64 | 943291317 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | — | 350 OYSTER POINT BOULEVARD | SOUTH SAN FRANCISCO | CA | 94080 | UNITED STATES | US | (650) 624-3000 | 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 | 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 | — | — | 1997 | Robert Blum | 423 | https://cytokinetics.com | 5,600,000,000 | 118,209,139 | 119,657,156 | Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. | 2025-10-10 20:02:28 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 5,600,000,000 | 3,600,000,000 | 180 | 118,410,689 | 15,405,979 | 14.9566 |
| 2023 | 2,000,000,000 | 0 | 0 | 103,004,710 | 7,843,319 | 8.2421 |
| 2022 | 2,000,000,000 | 557,000,000 | 38.6001 | 95,161,391 | 10,305,354 | 12.1445 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Sung H. Lee | Principal Financial Officer | 2024 | 550,000 | 80,000 | 3,352,526 | 177,522 | 86,410 | 5,918,931 |
| Fady I. Malik | Executive Vice President | 2024 | 609,464 | 0 | 3,399,979 | 287,972 | 12,333 | 5,371,389 |
| Robert I. Blum | Principal Executive Officer | 2024 | 825,550 | 0 | 9,800,033 | 681,079 | 1,688 | 14,368,343 |
| Andrew M. Callos | Chief Commercial Officer, Executive Vice President | 2024 | 562,913 | 0 | 2,700,004 | 269,143 | 13,909 | 4,389,027 |
| Brett Pletcher | Chief Legal Officer, Executive Vice President | 2024 | 560,000 | 100,000 | 2,694,347 | 99,031 | 0 | 5,420,492 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 498 |
| 2023 | 423 |
| 2022 | 409 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 18,474,000 | 7,530,000 | 94,588,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 339,408,000 | 330,123,000 | 240,813,000 |
| General And Administrative Expenses | 215,314,000 | 173,612,000 | 177,977,000 |
| Operating Expenses | 554,722,000 | 503,735,000 | 418,790,000 |
| Operating Income | -536,248,000 | -496,205,000 | -324,202,000 |
| Net Income | -589,526,000 | -526,244,000 | -388,955,000 |
| Earnings Per Share Basic | -5.26 | -5.45 | -4.33 |
| Earnings Per Share Diluted | -5.26 | -5.45 | -4.33 |
| Weighted Average Shares Outstanding Basic | 111,979 | 96,524 | 89,825 |
| Weighted Average Shares Outstanding Diluted | 111,979 | 96,524 | 89,825 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 94,857,000 | 113,024,000 | 1,600,000 |
| Marketable Securities Current | 981,157,000 | 501,800,000 | 716,995,000 |
| Accounts Receivable | 16,650,000 | 1,283,000 | 147,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,107,940,000 | 628,051,000 | 795,186,000 |
| Marketable Securities Non Current | 145,055,000 | 40,534,000 | 46,708,000 |
| Property Plant And Equipment | 65,815,000 | 68,748,000 | 80,453,000 |
| Other Assets Non Current | 7,705,000 | 7,996,000 | 9,691,000 |
| Total Assets Non Current | 293,733,000 | 196,265,000 | 219,589,000 |
| Total Assets | 1,401,673,000 | 824,316,000 | 1,014,775,000 |
| Accounts Payable | 20,369,000 | 21,507,000 | 25,611,000 |
| Deferred Revenue | 52,370,000 | — | — |
| Short Term Debt | 11,520,000 | 10,080,000 | 10,295,000 |
| Other Liabilities Current | 9,814,000 | 10,559,000 | 2,081,000 |
| Total Liabilities Current | 179,674,000 | 102,678,000 | 84,617,000 |
| Long Term Debt | 619,521,000 | 639,268,000 | 649,563,000 |
| Other Liabilities Non Current | 0 | 186,000 | 1,044,000 |
| Total Liabilities Non Current | 1,357,371,000 | 1,107,961,000 | 1,038,058,000 |
| Total Liabilities | 1,537,045,000 | 1,210,639,000 | 1,122,675,000 |
| Common Stock | 118,000 | 102,000 | 94,000 |
| Retained Earnings | -2,701,764,000 | -2,112,238,000 | -1,585,994,000 |
| Accumulated Other Comprehensive Income | 2,398,000 | -10,000 | -3,590,000 |
| Total Shareholders Equity | -135,372,000 | -386,323,000 | -107,900,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 9,531,000 | 11,892,000 | 5,814,000 |
| Share Based Compensation Expense | 97,840,000 | 72,065,000 | 47,853,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 15,367,000 | 1,136,000 | -56,672,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -4,483,000 | -3,483,000 | 4,524,000 |
| Change In Other Liabilities | 14,182,000 | 17,103,000 | 10,844,000 |
| Cash From Operating Activities | -395,890,000 | -414,333,000 | -299,516,000 |
| Purchases Of Marketable Securities | 1,293,416,000 | 635,211,000 | 855,393,000 |
| Sales Of Marketable Securities | 0 | 4,975,000 | 0 |
| Acquisition Of Property Plant And Equipment | 3,906,000 | 1,416,000 | 11,335,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -553,097,000 | 239,253,000 | -262,134,000 |
| Tax Withholding For Share Based Compensation | 19,631,000 | 10,517,000 | 9,602,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 93,640,000 | 164,233,000 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 8,679,000 | — | 47,651,000 |
| Other Financing Activities | 53,016,000 | 18,459,000 | 17,543,000 |
| Cash From Financing Activities | 930,611,000 | 221,317,000 | 516,166,000 |
| Change In Cash | -18,167,000 | 46,217,000 | -45,484,000 |
| Cash At End Of Period | 94,857,000 | 113,024,000 | 1,600,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 25,970,000 | 10,295,000 | 15,165,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -5.26 | -5.45 | -4.33 |
| Price To Earnings Ratio | -8.943 | -15.3193 | -10.582 |
| Earnings Growth Rate | -3.4862 | 25.8661 | — |
| Price Earnings To Growth Ratio | 2.5652 | -0.5923 | — |
| Book Value Per Share | -1,208.9052 | -4,002.3517 | -1,201.2246 |
| Price To Book Ratio | -0.0389 | -0.0209 | -0.0381 |
| Ebitda | -542,294,000 | -486,046,000 | -363,727,000 |
| Enterprise Value | 541,451,492.16 | 544,382,788.76 | 662,373,781.5 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -4.6615 | -1.6808 | -6.1155 |
| Capital Expenditures | 6,598,000 | 187,000 | 12,996,000 |
| Free Cash Flow | -402,488,000 | -414,520,000 | -312,512,000 |
| Return On Equity | 4.3549 | 1.3622 | 3.6048 |
| One Year Beta | 1.2359 | 1.3166 | 1.0069 |
| Three Year Beta | 1.0977 | 1.1105 | 0.9443 |
| Five Year Beta | 0.9926 | 0.9849 | 1.0246 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Blum Robert I | Director, President & CEO | 2025-10-16 | 5,000 | D | 363,108 |
| Wysenski Nancy | Director | 2025-10-15 | 99 | A | 30,873 |
| Kaye Edward M. MD | Director | 2025-10-15 | 199 | A | 9,977 |
| HENDERSON JOHN T | Director | 2025-10-15 | 338 | A | 74,578 |
| Harrington Robert Arthur | Director | 2025-10-15 | 199 | A | 20,692 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lisa McClain | 2025-08-13 | MI09 | Sale | 2025-06-17 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-11 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Capital Advisors, Ltd. LLC | 2025-09-30 | 9,000 | 164 | 54.878 |
| Blue Trust, Inc. | 2025-09-30 | 275 | 5 | 55 |
| Financial Management Professionals, Inc. | 2025-09-30 | 275 | 5 | 55 |
| CWM, LLC | 2025-09-30 | 27,000 | 489 | 55.2147 |
| Pacer Advisors, Inc. | 2025-09-30 | 865,070 | 15,740 | 54.96 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Fund | CFSLX | 5,265 | 186,012.45 | 0.0388 |
| Pacer Funds Trust | 2025-07-31 | Pacer Trendpilot US Mid Cap ETF | PTMC | 16,948 | 637,922.72 | 0.1522 |
| Direxion Shares ETF Trust | 2025-07-31 | Direxion Daily Mid Cap Bull 3X Shares | MIDU | 2,082 | 78,366.48 | 0.105 |
| AMG Funds IV | 2025-07-31 | CLASS Z SHARES | ACWZX | 9,950 | 374,518 | 1.0346 |
| AMG Funds IV | 2025-07-31 | CLASS I SHARES | ACWIX | 9,950 | 374,518 | 1.0346 |